个体化经颅磁刺激治疗卒中后视空间忽略的临床研究

注册号:

Registration number:

ChiCTR2600127096 

最近更新日期:

Date of Last Refreshed on:

2026-06-24 15:44:33 

注册时间:

Date of Registration:

2026-06-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

个体化经颅磁刺激治疗卒中后视空间忽略的临床研究

Public title:

Clinical study on individualized transcranial magnetic stimulation therapy for post-stroke visual spatial neglect

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于TMS-EEG评估指导个体化经颅磁刺激治疗卒中后视空间忽略的临床研究

Scientific title:

Clinical study on individualized transcranial magnetic stimulation therapy for post-stroke visual spatial neglect guided by TMS-EEG

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

叶琳琳 

研究负责人:

叶琳琳 

Applicant:

Linlin Ye 

Study leader:

Linlin Ye 

申请注册联系人电话:

Applicant telephone:

+86 10 83198716

研究负责人电话:

Study leader's
telephone:

+86 18801081779

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

happinesslin@163.com

研究负责人电子邮件:

Study leader's E-mail:

happinesslin@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区长椿街45号

研究负责人通讯地址:

北京市西城区长椿街45号

Applicant address:

45 Changchun street, Xicheng District, Beijing

Study leader's address:

45 Changchun street, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital of Capital Medical University

研究负责人所在单位:

首都医科大学宣武医院

Affiliation of the Leader:

Xuanwu Hospital Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研审[2026]150号-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学宣武医院伦理委员会-B

Name of the ethic committee:

Ethics Committee of Xuanwu Hospital Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-29 00:00:00

伦理委员会联系人:

张卓然

Contact Name of the ethic committee:

Zhang Zhuoran

伦理委员会联系地址:

北京市西城区长椿街45号

Contact Address of the ethic committee:

45 Changchun street, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 83199270

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xwzhuoranzhang@163.com

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区长椿街45号

Primary sponsor's address:

45 Changchun street, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

北京市西城区长椿街45号

Institution
hospital:

Xuanwu Hospital Capital Medical University

Address:

45 Changchun street, Xicheng District, Beijing

经费或物资来源:

首都卫生发展科研专项

Source(s) of funding:

Capital Health Development Research Special Project

研究疾病:

卒中后视空间忽略  

Target disease:

post-stroke visual spatial neglect

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究针对卒中后视空间忽略(VSN)患者经颅磁刺激(TMS)疗效存在显著个体差异的临床难题,创新性地提出基于TMS-EEG神经生理评估的个体化靶点选择新策略。研究拟首先在健康人群中构建多靶点(前额叶、 顶叶、小脑)TMS-EEG响应数据库,建立以“额顶网络连接性与半球间相互作用”为判据的个体化靶点决策模型。进而通过一项随机对照试验,招募右半球卒中后VSN患者,比较基于该模型选择的个体化靶点刺激与常规固定靶点刺激的疗效差异。本项目旨在验证“机制驱动”的个体化神经调控范式在提升TMS治疗精准性和有效性方面的优越性,为克服卒中康复领域的“一刀切”困境提供新证据,并为推动精准神经康复的临床转化提供关键技术支撑。  

Objectives of Study:

Aiming at the clinical problem of significant individual differences in the efficacy of transcranial magnetic stimulation (TMS) in patients with visual spatial neglect (VSN) after stroke, this study innovatively proposed a new strategy of individualized target selection based on TMS-EEG neurophysiological evaluation. The study plans to first build a multi-target (prefrontal, parietal, cerebellar) TMS-EEG response database in healthy people, and establish an individualized target decision-making model based on the criterion of "frontoparietal network connectivity and interhemispheric interaction". Then through a randomized controlled trial, we recruited patients with VSN after stroke in the right hemisphere, and compared the efficacy difference between individualized target stimulation selected based on this model and conventional fixed target stimulation. This project aims to verify the superiority of the "mechanism driven" individualized neural regulation paradigm in improving the accuracy and effectiveness of TMS treatment, provide new evidence for overcoming the "one size fits all" dilemma in the field of stroke rehabilitation, and provide key technical support for promoting the clinical transformation of precision neural rehabilitation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.健康受试者排除标准:(1)有神经系统或精神系统疾病史;(2)有癫痫、高颅压、颅脑手术史;(3)妊娠或哺乳期女性;(4)合并严重心脏病、肝肾功能障碍等全身性疾病;(5)不能配合完成研究流程者(包括但不限于:沟通障碍、无法保持规定姿势等)。
2.视空间忽略患者排除标准包括:(1) 存在新的梗死、出血性病灶或其他提示临床恶化的情况;(2) 严重的不可矫正视力障碍或视野缺损;(3) 视野检查证实的偏盲;(4) 癫痫诊断;(5) 存在金属植入物;(6) 简易精神状态检查(MMSE)得分 ≤17;(7) 检查过程中不配合行为;(8) 近期使用三环类抗抑郁药物。

Exclusion criteria:

1.Exclusion criteria for healthy subjects: (1) history of neurological or psychiatric diseases; (2) A history of epilepsy, high intracranial pressure, and craniocerebral surgery; (3) Pregnant or lactating women; (4) Complicated with severe heart disease, liver and kidney dysfunction and other systemic diseases; (5) Those who cannot cooperate with the completion of the research process (including but not limited to: communication barriers, inability to maintain the specified posture, etc.). 2.The exclusion criteria for patients with visuospatial neglect included: (1) the presence of new infarcts, hemorrhagic lesions or other conditions suggestive of clinical deterioration; (2) Severe uncorrectable visual impairment or visual field defect; (3) Hemianopia confirmed by perimetry; (4) ; (5) Presence of metal implants; (6) MMSE score <= 17; (7) Uncooperative behavior during inspection; (8) Recent use of tricyclic antidepressants.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-07-01 00:00:00 To 2028-12-01 00:00:00

干预措施:

Interventions:

组别:

视空间忽略患者对照组

样本量:

29

Group:

Control group of patients with visuospatial neglect

Sample size:

干预措施:

采用固定靶点刺激,选择左顶叶(L-PPC)作为刺激位点进行 TMS刺激。

干预措施代码:

Intervention:

The left parietal lobe (l-ppc) was selected as the stimulation site for TMS stimulation.

Intervention code:

组别:

视空间忽略患者试验组

样本量:

29

Group:

Experimental group of patients with visuospatial neglect

Sample size:

干预措施:

通过 TMS-EEG 计算额顶网络的连接性指标并结合半球间相互作用指标(IHI)赋予符号(±1),确定个体化的最佳刺激靶点(L-DLPFC、L-PPC 或 L-Cerebellum)后进行 TMS刺激。

干预措施代码:

Intervention:

TMS-EEG was used to calculate the connectivity index of the frontal parietal network, and the interhemispheric interaction index (IHI) was used to assign a symbol (+/- 1), and the best individualized stimulation target (l-dlpfc, l-ppc or l-cerebellum) was determined before TMS stimulation.

Intervention code:

组别:

健康受试组

样本量:

34

Group:

Healthy subjects

Sample size:

干预措施:

单次高频重复经颅磁刺激

干预措施代码:

Intervention:

Single high frequency repetitive transcranial magnetic stimulation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院 

单位级别:

三级甲等 

Institution
hospital:

Xuanwu Hospital Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

纸笔量表(直线二等分、线段划消、圆圈划消)

指标类型:

主要指标

Outcome:

Paper and pencil scale (line bisector, line segment elimination, circle elimination)

Type:

Primary indicator

测量时间点:

治疗前后及随访3个月

测量方法:

患者完成纸笔测试量表(直线二等分、线段划消、圆圈划消)

Measure time point of outcome:

Before and after treatment and follow-up for 3 months

Measure method:

The patient completes the paper and pencil test scale (line bisector, line segment elimination, circle elimination) test

指标中文名:

信号在皮层间的传播

指标类型:

次要指标

Outcome:

Propagation between signal cortices

Type:

Secondary indicator

测量时间点:

治疗前后

测量方法:

脑电信号使用 TMS 兼容 EEG 系统(PN-NET/32)采集,电极为 Ag/AgCl 电极,按 10-10 国际系统放置于脑电帽上。

Measure time point of outcome:

Before and after treatment

Measure method:

The EEG signals were collected using TMS compatible EEG system (PN-NET/32), with Ag/AgCl electrodes placed on the EEG cap according to the 10-10 international system.

指标中文名:

震荡活动

指标类型:

次要指标

Outcome:

oscillatory activity

Type:

Secondary indicator

测量时间点:

治疗前后

测量方法:

脑电信号使用 TMS 兼容 EEG 系统(PN-NET/32)采集,电极为 Ag/AgCl 电极,按 10-10 国际系统放置于脑电帽上。

Measure time point of outcome:

Before and after treatment

Measure method:

The EEG signals were collected using TMS compatible EEG system (PN-NET/32), with Ag/AgCl electrodes placed on the EEG cap according to the 10-10 international system.

指标中文名:

TMS 诱发电位(TEPs)

指标类型:

次要指标

Outcome:

TMS evoked potentials (TEPs)

Type:

Secondary indicator

测量时间点:

治疗前后

测量方法:

脑电信号使用 TMS 兼容 EEG 系统(PN-NET/32)采集,电极为 Ag/AgCl 电极,按 10-10 国际系统放置于脑电帽上。

Measure time point of outcome:

Before and after treatment

Measure method:

The EEG signals were collected using TMS compatible EEG system (PN-NET/32), with Ag/AgCl electrodes placed on the EEG cap according to the 10-10 international system.

指标中文名:

三种刺激靶点的综合神经反应分数(PLV_AUC 与 CD_AUC 之和)在干预前后的差异。

指标类型:

主要指标

Outcome:

The difference of the comprehensive neural response scores (the sum of plv_auc and cd_auc) of the three stimulation targets before and after the intervention.

Type:

Primary indicator

测量时间点:

单次TMS后

测量方法:

PLV_AUC(相位同步指标) 与 CD_AUC (电流密度)之和

Measure time point of outcome:

After a single TMS

Measure method:

The sum of PLV_AUC (Phase Synchronization Index) and CD-AUC (Current Density)

指标中文名:

静息态功能连接网络特征

指标类型:

次要指标

Outcome:

Characteristics of functional connectivity network in resting state

Type:

Secondary indicator

测量时间点:

治疗前后

测量方法:

功能性核磁共振扫描仪为GE Discovery MR 750w 3.0T,数据记录软件为AW4.7。

Measure time point of outcome:

Before and after treatment

Measure method:

The functional MRI scanner is GE Discovery MR 750w 3.0T, and the data recording software is AW4.7.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

委托我院循证医学专家应用SPSS22.0制作随机数,采用信封抽签分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The experts of evidence-based medicine in our hospital were entrusted to use spss22.0 to make random numbers, and the envelopes were used to draw lots for grouping.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

对研究参与者、研究者设盲

Blinding:

Blinding research participants and researchers

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF 表由相关研究人员填写,每个入选病例必须完成 CRF 表及电子数据采集系统(Electronic Data Capture System,EDC)的数据录入。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The CRF form is completed by the relevant researchers, and each selected case must complete the CRF form and the data entry of the Electronic Data Capture System (EDC).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-24 15:44:05